Preview Mode Links will not work in preview mode

This Week in Cardiology

Feb 19, 2021

Bernard Lown, Type 2 MI, Sacubitril/Valsartan and COVID19 anticoagulation are discussed in this week’s podcast. To read a partial transcript or to comment


Israeli Study Finds Pfizer Vaccine 95% Effective Against COVID-19

Bernard Lown

Cardiologist, Antiwar Activist Bernard Lown Dies at 99

Type 2 MI

New Light Cast on Type-2 MI Aims to Sharpen Diagnosis, Therapy

Early AC in COVID19

More Evidence Supports Early Anticoagulation in COVID-19


FDA Expands Sacubitril/Valsartan Indication to Embrace Some HFpEF

Five Reasons Sacubitril/Valsartan Should NOT Be Approved for HFpEF

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact